Member Info for LordSnooty

Parps - I see no reason why, XBIO having qualified with thirty days closing above $4 a couple of weeks ago, the SEC decision on NASDAQ has to wait the full sixty days. What more can possibly be achieved by that? Can you point to where it says that is required?

have put UK shareholders through the wringer with this share - not just once but twice in the past two years - with their risible 'fast track' to NASDAQ, expounded in late 2013 when we were still on AIM; I clearly recall the gung-ho bullishness at that stage - the Board thought they'd found a backdoor to a simple uplist to NASDAQ through OTC, and consequent easy-terms funding. Well we the shareholders have suffered the consequences of that mistake, but it appears nobody on our Board has fallen on their sword - unless Colin Hill's retirement can be considered as such; in fact quite the contrary, it appears, as share options and lavish salaries continued to be dished out even as we languished. That's water under the bridge about which, with the Company's shareholding structured as it is, we can do nothing now. However, after seven months since OPKO took a stake - seven months of almost complete, apparently enforced, silence from the Company, as we await THE DECISION - during which time the share price has dwindled to a few cents old-style - you might be forgiven for surrendering your now almost worthless holding to the circling sharks. However, we are at such a pretty pass now, where all remaining UK holders from the AIM days are in negative territory, that it is scarely worth selling - and the prize of a drug candidate that actually works here, a licensing-out there, continues to tantalise.

5teveW - same as has been happening since we arrived on OTC - terrible liquidity means that anyone wanting to dispose of a few thousand shares in one session knocks the SP down 20%, and right now we are perceived as a poor risk - no cash, asking for an IPO of $35m, dependent on SEC approval for NASDAQ - so there's little support. If and when we get the SEC go-ahead to uplist, and if the roadshow demonstrates there are serious professionals interested in investing in XBIO, we should see a rerate. Until then, it's grit your teeth time.

Except us. We drop 20% on thin air.

in succession! Must be something up....

Exactly - another mouth to feed and down a further five percent - now worth less than 15c options before consolidation.

All that remains to know is the IPO price and the exercise price.

Yorkie - I sincerely hope so, 'they' have been selling cheap (15c unconsolidated) shares at marginally above cost for weeks now in order to pump liquidity in where, under normal circumstances, there is none; just to put us back the notional price where OPKO 'bought in' - 49c, would mean an SP of $16.17, more than three times where we are now. If you look at the most recent iteration of the uplist proposal (S1/A of 24/6/16), published last week, p.3, you'll get a good idea of news due - EPO India was due last quarter, is as usual late. EPO Oz is due this quarter. Filings for various Virexxa applications are also due H2, all being well with fund raising.

5teve - next Tuesday is just the day by which, if the SP stays above $4, XBIO will have met one of the key criteria for SEC approval to uplist to NASDAQ. That doesn't necessarily mean approval will follow immediately, though we all hope it will - that's up to the SEC.

5teveW - if it's any consolation, all of us UK holders are sucking up a nasty paper loss after 2 1/2 years on this disaster called OTC, but I do believe the company must have some decent news to bolster the IPO - after all, they want $20m from the market and it's in their interest to achieve as little dilution for those funds as possible.

5teveW - it's a manufactured market, it will hold above $4 in worst-case scenario - remember that Baxter (as was) paid $0.935 per share for their holding two and a half years ago. OPKO paid $0.49 per share (diluted) five months ago for their holding. Wait for the roadshow, EPO news and then see IPO price. Miserable times for another month but then should improve.

XBIOD started trading after the reverse split on 1st June. As of today it has had 8 days above the minimum price of $4. Thus another 22 trading days are required, which will take us to 11th July, there being a holiday on 4th July. After that date we can expect to have SEC approval, followed by roadshow and IPO before uplist. I would guess the IPO to take place early/mid August.

...and flat on our faces again. This share is going nowhere until the SEC make up their minds whether or not we can go play with the big boys on NASDAQ.

Total 95.33m shares in issue, not 94.33m.

There is no dilution with a reverse split; instead of formerly owning 10 shares at say $0.30, you now own 1 share at $3.00. The product is the same - $3. They say they plan to raise $20m in the IPO, so dilution from IPO depends on price they set. For example, if IPO is set at $10, they will issue two million shares. In addition to the 93.33m shares we have in issue now, after the consolidation (308m/33). With IPO at $10, that would make total shares in issue 94.33m shares. All eyes are now on next steps: 1. SEC approval to uplist. 2. Roadshow to drum up interest and discover IPO price. 3. Any news to support IPO? 4. IPO price. 5. Price after uplist.

http://www.bizjournals.com/boston/blog/bioflash/2016/06/lexington-biotech-xenetic-biosciences-aims-to.html?ana=RSS%26s%3Darticle_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_boston+%28Boston+Business+Journal%29

Boogie - yup, it's $4. It's also a formality, barring catastrophic trial data or some such. Looks like the plan is not to worry about volume at this stage, but if we get news or approval to uplist, that may change. All eyes now on green light from SEC, which could happen any day.

http://www.asx.com.au/asxpdf/20160531/pdf/437lnwqq6d2wrj.pdf

Whittled it down to 156,800 on the ask now. At this rate it'll be blue sky by the end of the year.

Guess? July/August.